GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Hold” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given an average rating of “Hold” by the fifteen ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $3.8125.

Several research analysts have issued reports on the stock. Citigroup reissued a “buy” rating on shares of GoodRx in a research report on Thursday. Weiss Ratings cut shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday. TD Cowen increased their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $3.50 price target on shares of GoodRx in a report on Friday, May 8th.

GoodRx Price Performance

GDRX stock opened at $2.96 on Monday. The company has a market capitalization of $1.01 billion, a P/E ratio of 49.34, a PEG ratio of 1.37 and a beta of 1.60. GoodRx has a twelve month low of $1.77 and a twelve month high of $5.81. The business has a 50 day simple moving average of $2.83 and a 200-day simple moving average of $2.51. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.78.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The business had revenue of $194.01 million for the quarter, compared to analysts’ expectations of $185.40 million. During the same period in the previous year, the company posted $0.09 EPS. The company’s quarterly revenue was down 4.4% on a year-over-year basis. As a group, equities analysts anticipate that GoodRx will post 0.17 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP acquired a new position in shares of GoodRx in the third quarter valued at approximately $33,000. Cetera Investment Advisers acquired a new stake in shares of GoodRx during the second quarter worth $50,000. Boothbay Fund Management LLC acquired a new stake in shares of GoodRx during the third quarter worth $43,000. Meridian Wealth Management LLC purchased a new position in GoodRx in the 4th quarter valued at $29,000. Finally, Shay Capital LLC purchased a new position in GoodRx in the 3rd quarter valued at $47,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.